

Treatment-Experienced

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Source: Poordad F, et al. Hepatology. 2018;67:1253-60.

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features

MAGELLAN-1 (Part 2) Trial

- **Design:** Randomized, open-label, multicenter, phase 3 trial to evaluate the safety and efficacy of glecaprevir-pibrentasvir for 12 or 16 weeks in patients with genotype 1 or 4 chronic HCV (with or without cirrhosis) who previously experienced virologic failure with direct-acting antiviral (DAA) therapy.
- **Setting:** 31 sites in Australia, France, Spain, UK and US
- **Key Eligibility Criteria**
 - Chronic HCV GT 1, 4, 5, or 6
 - HCV RNA >1,000 IU/mL at screening
 - At least 18 years old (no upper limit)
 - Prior failure with ≥ 1 NS3/4A protease and/or NS5A inhibitor-based regimen
 - Patients without cirrhosis or with compensated cirrhosis
 - Patients with HIV or HBV coinfection excluded
- **Primary End-Point:** SVR12

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Regimens

Week

0

12

16

24

28

n = 44

Glecaprevir-Pibrentasvir
(300/120 mg) once daily

SVR12

GT 1
(n = 87)

or

GT 4
(n = 4)

n = 47

Glecaprevir-Pibrentasvir
(300/120 mg) once daily

SVR12

Randomized 1:1 ratio to 12 or 16 weeks; stratified by genotype and past NS5A experience


Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Baseline Characteristics

Characteristics	Glecaprevir-Pibrentasvir 12 weeks (n = 44)	Glecaprevir-Pibrentasvir 16 weeks (n = 47)
Age, median years (range)	57 (22-67)	56 (36-70)
Male sex, n (%)	31 (70)	33 (70)
Black race, n (%)	9 (20)	11 (23)
BMI, median kg/m ² (range)	28 (21-41)	29 (20-52)
IL28B non-CC genotype, n (%)	38 (86)	42 (89)
HCV RNA, median log ₁₀ IU/ml (range)	6.1 (4.7-7.2)	6.3 (4.7-7.1)
HCV Subtype, n (%)		
1a	35 (80)	32 (71)
1b	8 (18)	11 (23)
1c	-	1 (2)
4	1 (2)	3 (6)
Compensated cirrhosis, n (%)	15 (34)	12 (26)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Baseline Characteristics

Characteristics	Glecaprevir-Pibrentasvir 12 weeks (n = 44)	Glecaprevir-Pibrentasvir 16 weeks (n = 47)
Prior DAA class, n (%)		
NS3/4A PI only (NS5A inhibitor naïve)	14 (32)	13 (28)
NS5A inhibitor only (PI-naïve)	16 (36)	18 (30)
N3/4A PI + NS5A inhibitor	14 (32)	16 (34)
Past DAA response, n (%)		
On-treatment failure	14 (32)	13 (28)
Virologic relapse	30 (68)	34 (72)
Key baseline substitutions, n (%)		
None	13 (30)	13 (30)
NS3 only	2 (5)	4 (9)
NS5A only	24 (55)	23 (52)
NS3 and NS5A	5 (11)	4 (9)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Results



Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Results by Prior DAA Class

Sustained Virologic Response		
Response	Glecaprevir-Pibrentasvir 12 weeks (n = 44)	Glecaprevir-Pibrentasvir 16 weeks (n = 44)
Overall	39/44 (89)	43/47 (91)
On-treatment virologic failure	1/44 (2)	4/47 (9)
Virologic relapse	4/44 (9)	0/47 (0)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Results by Prior DAA Class

Sustained Virologic Response Based on Prior DAA Class

Prior DAA Class	Glecaprevir-Pibrentasvir 12 weeks (n = 44)	Glecaprevir-Pibrentasvir 16 weeks (n = 44)
NS3/4A PI only	14/14 (100)	13/13 (100)
NS5A inhibitor only	14/16 (88)	17/18 (94)
NS3/4A PI + NS5A inhibitor	11/14 (79)	13/16 (81)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Results by Baseline Substitutions

Sustained Virologic Response Based on Baseline Substitutions

Baseline Substitutions	Glecaprevir-Pibrentasvir 12 weeks (n = 44)	Glecaprevir-Pibrentasvir 16 weeks (n = 44)
None	13/13 (100)	13/13 (100)
NS3 only	2/2 (100)	4/4 (100)
NS5A only	20/24 (83)	22/23 (96)
NS3 and NS5A	4/5 (80)	1/4 (25)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Conclusions

Conclusions: “Patients with hepatitis C virus (HCV) who have virologic failure after treatment containing an NS5A inhibitor have limited retreatment options.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.